Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
10x Genomics (TXG) Stock Price & Analysis
744 Followers
TXG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$24.60 - $63.57
Previous Close$25.01
Volume1.57M
Average Volume (3M)1.59M
Market Cap
$2.99B
Enterprise Value$2.71B
Total Cash (Recent Filing)$371.81M
Total Debt (Recent Filing)$92.18M
Price to Earnings (P/E)-11.2
Beta2.44
Next Earnings
Aug 01, 2024EPS Estimate
-$0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.24
Shares Outstanding119,708,426
10 Day Avg. Volume1,636,167
30 Day Avg. Volume1,590,497
Standard Deviation0.17
R-Squared0.38
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)4.29
Price to Sales (P/S)18.74
Price to Cash Flow (P/CF)-47.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.34
Enterprise Value/Gross Profit6.63
Enterprise Value/Ebitda-12.90
Forecast
1Y Price Target
$41.73Price Target Upside66.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
10x Genomics News
Bulls Say, Bears Say
Bulls Say
Financial OutlookThe initial 2024 revenue guidance is considered achievable, with the company positioned to revise the range upward throughout the year, suggesting a strong financial performance ahead.
Market LeadershipTXG is developing a best in class spatial platform and is expected to continue to lead the market, with new products like GEM-X and Visium HD enhancing its competitive position.
Product LaunchNew product introductions, especially in spatial genomics, are seeing strong customer interest, which is expected to drive higher demand and increased revenue.
Bears Say
Competitive PositionLingering questions about the company's competitive position and gross margin stability.
Financial Performance10x Genomics reported 1Q sales lower than expected, missing both Bank of America and Street estimates.
Market ExpectationsThe company's FY24 revenue guidance is below the consensus expectations, suggesting potential challenges ahead.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TXG FAQ
What was 10x Genomics Inc’s price range in the past 12 months?
10x Genomics Inc lowest stock price was $24.60 and its highest was $63.57 in the past 12 months.
What is 10x Genomics Inc’s market cap?
Currently, no data Available
When is 10x Genomics Inc’s upcoming earnings report date?
10x Genomics Inc’s upcoming earnings report date is Aug 01, 2024 which is in 74 days.
How were 10x Genomics Inc’s earnings last quarter?
10x Genomics Inc released its earnings results on Apr 30, 2024. The company reported -$0.5 earnings per share for the quarter, the consensus estimate of -$0.5 by $0.
Is 10x Genomics Inc overvalued?
According to Wall Street analysts 10x Genomics Inc’s price is currently Undervalued.
Does 10x Genomics Inc pay dividends?
10x Genomics Inc does not currently pay dividends.
What is 10x Genomics Inc’s EPS estimate?
10x Genomics Inc’s EPS estimate is -$0.48.
How many shares outstanding does 10x Genomics Inc have?
10x Genomics Inc has 105,651,596 shares outstanding.
What happened to 10x Genomics Inc’s price movement after its last earnings report?
10x Genomics Inc reported an EPS of -$0.5 in its last earnings report, expectations of -$0.5. Following the earnings report the stock price went down -8.06%.
Which hedge fund is a major shareholder of 10x Genomics Inc?
Among the largest hedge funds holding 10x Genomics Inc’s share is ARK Investment Management LLC. It holds 10x Genomics Inc’s shares valued at 226M.
---
10x Genomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.73 (66.85% Upside)
$41.73 (66.85% Upside)
Blogger Sentiment
Bullish
TXG Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 292.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $543.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.39%
12-Months-Change
Fundamentals
Return on Equity
-34.75%
Trailing 12-Months
Asset Growth
-8.99%
Trailing 12-Months
Company Description
10x Genomics Inc
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.
---
TXG Earnings Call
Q1 2024
0:00 / 0:00
---
TXG Revenue Breakdown
77.51% Consumables
19.96% Instruments
2.54% Services
---
TXG Stock 12 Month Forecast
Average Price Target
$41.73
▲(66.85% Upside)
Technical Analysis
Best Analysts Covering TXG
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+54.49%
initiated a buy rating 5 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +54.49% per trade.
---